Tag - Chronix Biomedical

Chronix provides update on studies & presentations

Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, is pleased to report the successful outcome of two pilot studies of its liquid biopsy test for assessing the response to treatment in different solid tumour types. Chronix’s tests use proprietary algorithms to derive a copy number instability (CNI) score from sequencing of circulating cell-free tumour DNA (cfDNA), which can be used in the prognosis, diagnosis and monitoring of therapeutic response to cancer. Read more >>